JP2020529457A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020529457A5 JP2020529457A5 JP2020506940A JP2020506940A JP2020529457A5 JP 2020529457 A5 JP2020529457 A5 JP 2020529457A5 JP 2020506940 A JP2020506940 A JP 2020506940A JP 2020506940 A JP2020506940 A JP 2020506940A JP 2020529457 A5 JP2020529457 A5 JP 2020529457A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- compound
- nhr
- linker
- moiety
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 17
- 238000000034 method Methods 0.000 claims 5
- 230000008685 targeting Effects 0.000 claims 3
- 150000001412 amines Chemical class 0.000 claims 2
- 125000003277 amino group Chemical group 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000002194 synthesizing effect Effects 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17185598 | 2017-08-09 | ||
| EP17185598.4 | 2017-08-09 | ||
| PCT/EP2018/071507 WO2019030284A1 (en) | 2017-08-09 | 2018-08-08 | NOVEL TARGETED CYTOTOXIC RATJADONE DERIVATIVES AND CONJUGATES THEREOF |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020529457A JP2020529457A (ja) | 2020-10-08 |
| JP2020529457A5 true JP2020529457A5 (cg-RX-API-DMAC10.html) | 2021-09-24 |
| JP7218351B2 JP7218351B2 (ja) | 2023-02-06 |
Family
ID=59579518
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020506940A Active JP7218351B2 (ja) | 2017-08-09 | 2018-08-08 | 新たな標的化された細胞傷害性ラトジャドン誘導体及びそのコンジュゲート |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11236059B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3665161B1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP7218351B2 (cg-RX-API-DMAC10.html) |
| AU (1) | AU2018315154B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3072399A1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2019030284A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220211860A1 (en) * | 2019-05-02 | 2022-07-07 | The University Of Sydney | Peptide derivatives and conjugates thereof for treating cancer |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| ATE127476T1 (de) * | 1990-04-06 | 1995-09-15 | Univ Tulane | Lhrh-analoge. |
| DE19636721A1 (de) | 1996-09-10 | 1998-03-12 | Biotechnolog Forschung Gmbh | Antibiotische und antitumorale Verbindung, Herstellungsverfahren, Mittel und DSM 11 071 |
| DE10106647A1 (de) | 2001-02-12 | 2002-08-22 | Univ Hannover | Ratjadon-Derivate zum Hemmen des Zellwachstums |
| EP1391213A1 (en) | 2002-08-21 | 2004-02-25 | Boehringer Ingelheim International GmbH | Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents |
| US7446196B2 (en) | 2004-06-03 | 2008-11-04 | Kosan Biosciences, Incorporated | Leptomycin compounds |
| US7541330B2 (en) | 2004-06-15 | 2009-06-02 | Kosan Biosciences Incorporated | Conjugates with reduced adverse systemic effects |
| CA2653953C (en) * | 2006-06-01 | 2015-12-08 | Schering-Plough Healthcare Products, Inc. | Phenylephrine pharmaceutical formulations and compositions for colonic absorption |
| EP1864682A1 (en) | 2006-06-09 | 2007-12-12 | Sanofi-Aventis | Leptomycin derivatives |
| FR2947269B1 (fr) | 2009-06-29 | 2013-01-18 | Sanofi Aventis | Nouveaux composes anticancereux |
| PT2528625E (pt) | 2010-04-15 | 2013-10-17 | Spirogen Sarl | Pirrolobenzodiazepinas e conjugados das mesmas |
| HRP20180268T4 (hr) | 2012-10-23 | 2026-03-27 | Synaffix B.V. | Modificirano antitijelo, konjugat antitijela i postupak za njihovu pripremu |
| WO2015012904A2 (en) | 2012-12-13 | 2015-01-29 | Immunomedics, Inc. | Antibody-sn-38 immunoconjugates with a cl2a linker |
| MX2016001541A (es) * | 2013-08-02 | 2016-08-18 | Sanofi Sa | Uso de anticuerpo inmunoconjugado anti-muc1 maitansinoide para el tratamiento de tumores solidos. |
-
2018
- 2018-08-08 US US16/637,257 patent/US11236059B2/en not_active Expired - Fee Related
- 2018-08-08 AU AU2018315154A patent/AU2018315154B2/en not_active Ceased
- 2018-08-08 EP EP18749385.3A patent/EP3665161B1/en active Active
- 2018-08-08 JP JP2020506940A patent/JP7218351B2/ja active Active
- 2018-08-08 WO PCT/EP2018/071507 patent/WO2019030284A1/en not_active Ceased
- 2018-08-08 CA CA3072399A patent/CA3072399A1/en active Pending